Due to its crucial role, TOP2A has been identified as a primary target for developing anti-tumor chemotherapeutic drugs that inhibit its DNA-cleaving activity, such as doxorubicin, etoposide, and mitoxantrone (Liu et al., 2019). This evidence concerns the gene TOP2A and neoplasm.